Oxford Diagnostics Laboratories Imugen test for Lyme and Co-Infections

The company has lots of websites.

Here's why:  Oxford Immunotec Enters into Definitive Agreement to Acquire Imugen

http://www.oxfordimmunotec.com/international/

Management Team

Board of Directors

http://www.imugen.com/

http://www.oxfordimmunotec.com/north-america/products-services/tick-borne-disease/imugen/

Over 25 years ago, a small team of Massachusetts Department of Public Health State Laboratory employees, working alongside leading clinicians in the emerging area of Lyme disease, recognized that the diagnostic tools available to physicians and laboratories were limited. This motivated team knew patients deserved better and in 1989 founded Imugen. The roots of Imugen began in providing fast, trusted and accessible testing for evidence of Borrelia burgdorferi infection, the infection that causes Lyme disease. Over time, these founding principles have been applied to other tick-borne infections and have grown to represent a menu of Imugen testing services.

Innovation remains embedded in Imugen's testing services, with progressive PCR and serology test offerings. This comprehensive testing including PCR and serology may offer a greater opportunity to detect evidence of tick-borne infection.* Other innovations include a robust, internal database of infection positivity rates by region, the identification of Borrelia miyamotoi infection in the first clinical case in the United States in 2012 and, most recently, the completion of a three-year clinical trial to evaluate a testing algorithm for detecting Babesia microti in donated blood.

In 2016, Imugen became part of the Oxford Immunotec family through an acquisition. Testing services are being expanded beyond the Northeast to provide clinicians across the United States with comprehensive testing solutions for tick-borne infections.

Clinical Trial: https://clinicaltrials.gov/ct2/show/NCT03201042    (See contact people at the end of the page noting its immunotec)

Oxford Immunotec Announces Update in Patent Infringement Litigation

"While we are disappointed that the court did not grant a preliminary injunction prohibiting the sale of Qiagen's QFT-Plus product in the U.S. before trial, we are encouraged by the court's rulings on the issues of validity and obviousness," said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec. "We continue to look forward to the further defense of our patents at the upcoming trial in January."

Oxford Immunotec and QIAGEN N.V. Settle Patent Infringement Lawsuit